Febrile Neutropenia Pipeline and Clinical Trials Assessment (2023) | Companies- Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Pfizer, Mylan, Viatris Inc, Sanofi an

DelveInsight's report titled "Febrile Neutropenia Pipeline Insight 2023" offers extensive information on more than 10+ companies and over 10+ pipeline drugs in the field of Febrile Neutropenia research. The report encompasses detailed profiles of the pipeline drugs for Febrile Neutropenia, including information on clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

For the Febrile Neutropenia emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, and route of administration, molecule type, and mechanism of action (MOA). The research on the Febrile Neutropenia pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, clinical trial studies conducted for Febrile Neutropenia, any NDA approvals obtained for Febrile Neutropenia, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

To explore more information on the latest breakthroughs in the Febrile Neutropenia Pipeline treatment landscape of the report, click here @ Febrile Neutropenia Pipeline Outlook- https://www.delveinsight.com/sample-request/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Febrile Neutropenia Pipeline Report
• DelveInsight's Febrile Neutropenia Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Febrile Neutropenia Companies are working in the market include Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Pfizer, Mylan, Viatris Inc, Sanofi, Amgen, Hoffmann-La-Roche, Janssen Pharma, Bayer, and others
• Promising Febrile Neutropenia Pipeline Therapies in the various development stages include Imipenem, linezolid, vancomycin, ciprofloxacin, cefepime, Teicoplanin, Vancomycin, pegfilgrastim, and others
• In May 2022, BeyondSpring presented new clinical data in the Chemotherapy-Induced Neutropenia.The DUBLIN-3 Phase 3 trial is a randomized, single blinded, active-controlled global trial that enrolled 559 patients with 2nd/3rd line NSCLC, EGFR wild type, with a measurable lung lesion. Patients were treated on a 21-day cycle with an infusion of docetaxel (75 mg/m2 on day 1) and plinabulin (30 mg/m2 on days 1 and 8) vs. docetaxel alone (75 mg/m2, day 1). The primary endpoint was overall survival. Secondary endpoints include ORR, PFS, grade 4 neutropenia, 2 year and 3 year OS rate and quality of life analysis. Plinabulin in combination with docetaxel (DP) showed statistically significant overall survival improvements compared to docetaxel alone (D) for the ITT population (DP: n=278; D: n=281).
• Plinabulin is a novel compound under investigation that belongs to a new category of selective immunomodulating microtubule-binding agents. It holds promise for preventing chemotherapy-induced neutropenia (CIN) and offering anticancer advantages. It possesses a distinct mode of action (MOA) when compared to existing chemotherapeutic treatments and conventional microtubule-binding agents. This leads to a unique safety and effectiveness profile.

Febrile Neutropenia Overview
Febrile Neutropenia is the most common serious and common complication of cancer therapy. Neutropenic fever is the most common and serious complication associated with hematopoietic cancers or with patients receiving chemotherapeutic regimens for cancer. Neutropenic fever occurs when a neutropenic patient encounters an infectious pathogen. In this immunocompromised state, patients lose or have weakened immunity to fend off infections.

For further information, refer to the detailed Febrile Neutropenia Unmet Needs, Febrile Neutropenia Market Drivers, and Febrile Neutropenia Market Barriers, click here for Febrile Neutropenia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Febrile Neutropenia Emerging Drugs Profile
• Plinabulin: BeyondSpring Pharmaceuticals
• And many others

Febrile Neutropenia Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies Febrile Neutropenia. The companies which have their Febrile Neutropenia drug candidates in the most advanced stage, i.e Phase III include, Daewoong Pharmaceutical.

Request a sample and discover the recent advances in Febrile Neutropenia Ongoing Clinical Trial Analysis and Medications, click here @ Febrile Neutropenia Treatment Landscape- https://www.delveinsight.com/sample-request/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Febrile Neutropenia Pipeline Therapeutic Assessment
• Febrile Neutropenia Assessment by Product Type
• Febrile Neutropenia Assessment by Stage and Product Type
• Febrile Neutropenia Assessment by Route of Administration
• Febrile Neutropenia Assessment by Stage and Route of Administration
• Febrile Neutropenia Assessment by Molecule Type
• Febrile Neutropenia Assessment by Stage and Molecule Type

Some of the Companies in the Febrile Neutropenia Therapeutics Market include-
Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Pfizer, Mylan, Viatris Inc, Sanofi, Amgen, Hoffmann-La-Roche, Janssen Pharma, Bayer, and others.

Dive deep into rich insights for drugs for Febrile Neutropenia Pipeline, click here @ Febrile Neutropenia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Febrile Neutropenia Pipeline Report
• Coverage- Global
• Febrile Neutropenia Companies- Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Pfizer, Mylan, Viatris Inc, Sanofi, Amgen, Hoffmann-La-Roche, Janssen Pharma, Bayer, and others
• Febrile Neutropenia Pipeline Therapies- Imipenem, linezolid, vancomycin, ciprofloxacin, cefepime, Teicoplanin, Vancomycin, pegfilgrastim, and others
• Febrile Neutropenia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Febrile Neutropenia Mergers and acquisitions, Febrile Neutropenia Licensing Activities @ Febrile Neutropenia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Febrile Neutropenia Executive Summary
3. Febrile Neutropenia: Overview
4. Febrile Neutropenia Pipeline Therapeutics
5. Febrile Neutropenia Therapeutic Assessment
6. Febrile Neutropenia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Fexuprazan: Daewoong Pharmaceutical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Netazepide: Trio Medicines
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Febrile Neutropenia Key Companies
21. Febrile Neutropenia Key Products
22. Febrile Neutropenia- Unmet Needs
23. Febrile Neutropenia- Market Drivers and Barriers
24. Febrile Neutropenia- Future Perspectives and Conclusion
25. Febrile Neutropenia Analyst Views
26. Febrile Neutropenia Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.